1. Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment
- Author
-
Sebastian Palmqvist, Nicholas C. Cullen, Nicholas K. Proctor, Erik Stomrud, Henrik Zetterberg, Pedro Pesini, Kaj Blennow, Leticia Sarasa, Oskar Hansson, Shorena Janelidze, José Antonio Allué, Niklas Mattsson-Carlgren, Jeffrey L. Dage, and Antoine Leuzy
- Subjects
Oncology ,medicine.medical_specialty ,Amyloid ,business.industry ,Neurofilament light ,Cognition ,Disease ,medicine.disease ,Clinical trial ,Neuroimaging ,Internal medicine ,mental disorders ,medicine ,Dementia ,Cognitive decline ,business - Abstract
We developed models for individualized risk prediction of cognitive decline in mild cognitive impairment (MCI), using plasma biomarkers of β-amyloid (Aβ), tau, and neurodegeneration. We included MCI patients from the Swedish BioFINDER study (n=148) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI; n=86 for model selection; n=425 for prognostic validation). The primary outcomes were longitudinal cognition and conversion to AD dementia, predicted by plasma Aβ42/Aβ40, P-tau181, and neurofilament light (NfL). A model which included P-tau181 and NfL, but not Aβ42/Aβ40, had the best performance (AUC=0.88 for four-year conversion to AD in BioFINDER, validated in ADNI). The prognostic ability of plasma biomarkers was stronger than a basic model of age, sex, education, and baseline cognition and similar to cerebrospinal fluid biomarkers. Plasma biomarkers, in particular P-tau181 and NfL, may be of high value to identify MCI individuals who will progress to AD dementia in clinical trials and in clinical practice.
- Published
- 2020
- Full Text
- View/download PDF